scholarly journals Guillain–Barré syndrome occurring synchronously with systemic lupus erythematosus as initial manifestation treated successfully with low-dose cyclophosphamide

2016 ◽  
Vol 6 (2) ◽  
pp. 30689 ◽  
Author(s):  
Naveed Ali ◽  
Ritesh Rampure ◽  
Faizan Malik ◽  
Syed Imran Mustafa Jafri ◽  
Deepa Amberker
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Low Dose ◽  
Guillain Barre Syndrome ◽  
Systemic Lupus ◽  
Initial Manifestation ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Fulminant Guillain-Barré syndrome in a patient with systemic lupus erythematosus

2019 ◽  
Vol 12 (1) ◽  
pp. bcr-2018-226634 ◽  
Author(s):  
Eric Anthony Coomes ◽  
Hourmazd Haghbayan ◽  
Jenna Spring ◽  
Sangeeta Mehta
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Axonal Neuropathy ◽  
Guillain Barre Syndrome ◽  
Systemic Lupus ◽  
Outward Appearance ◽  
Intravenous Immunoglobulin Therapy ◽  
Neuropsychiatric Manifestation ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

A 45-year-old man with a history of systemic lupus erythematosus presented with progressive weakness and areflexia. Electromyogram revealed reduced motor and sensory amplitudes without demyelinating features. He was clinically diagnosed with the acute motor and sensory axonal neuropathy variant of Guillain-Barré syndrome. Despite intravenous immunoglobulin therapy, he deteriorated with loss of all voluntary motor function and cranial nerve reflexes. Concomitant investigations revealed class V lupus nephritis. Therapy was initiated with plasma exchange, glucocorticoids and further immunosuppression, with gradual neurological recovery. We present the first documented case of fulminant Guillain-Barré syndrome as a neuropsychiatric manifestation of systemic lupus erythematosus, highlighting how immune-mediated polyneuropathy via diffuse deafferentation may mimic the outward appearance of brain death. While glucocorticoids are not indicated in idiopathic Guillain-Barré, when this neurological disorder is a consequence of systemic lupus erythematosus, immunomodulatory treatment should be initiated to prevent neurological deterioration.

A CASE OF SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING AS GUILLAIN-BARRÉ SYNDROME

Rheumatology ◽  
1989 ◽  
Vol 28 (5) ◽  
pp. 440-442 ◽  
Author(s):  
K. RAY CHAUDHURI ◽  
I. K. TAYLOR ◽  
R. M. NIVEN ◽  
R. J. ABBOTT
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Guillain Barre Syndrome ◽  
Systemic Lupus ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals GUILLAIN-BARRÉ SYNDROME AS A MANIFESTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS

2021 ◽  
Author(s):  
Gustavo Roberto Lourenço ◽  
Danielly Dantas Pimentel ◽  
Gizelle Gouvea Rezende ◽  
Iane Tamara Dondé ◽  
Taisa Morete da Silva ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Guillain Barre Syndrome ◽  
Systemic Lupus ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals A Case of Systemic Lupus Erythematosus Presenting as Guillain-Barré Syndrome

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Helen Chioma Okoh ◽  
Sandeep Singh Lubana ◽  
Spencer Langevin ◽  
Susan Sanelli-Russo ◽  
Adriana Abrudescu
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Disease ◽  
Complete Recovery ◽  
Multiple Organ ◽  
Guillain Barre Syndrome ◽  
High Morbidity ◽  
Systemic Lupus ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Systemic lupus erythematosus (SLE) is an autoimmune systemic disease with multiple organ involvement with high morbidity and mortality rate. Among the severe potential fatal complications are those of the central and peripheral nervous system which usually develop during the course of the disease and very rarely from the outset of the disease. We are reporting a rare case of Miller-Fisher (MFS) variant of Guillain-Barré syndrome (GBS) as the first manifestation of SLE in a 41-year-old female who progressed to flaccid paralysis with no neurological improvement with initial immunosuppressive therapy, plasmapheresis, and first cycle of intravenous immunoglobulin (IVIG) but with remarkable and complete recovery after the second 5-day course of IVIG.

Sign in / Sign up

Export Citation Format

Share Document